The Food and Drug Administration requested additional clinical data from Clovis Oncology Inc. (Nasdaq: CLVS) for its lung cancer treatment rociletinib. The stock price collapsed $69.19 to close at $30.24.
FDA asks Clovis Oncology for more data
November 16, 2015 at 18:07 PM EST
